CN113166081A - 用于治疗与nlrp活性相关的病症的化合物和组合物 - Google Patents

用于治疗与nlrp活性相关的病症的化合物和组合物 Download PDF

Info

Publication number
CN113166081A
CN113166081A CN201980078239.1A CN201980078239A CN113166081A CN 113166081 A CN113166081 A CN 113166081A CN 201980078239 A CN201980078239 A CN 201980078239A CN 113166081 A CN113166081 A CN 113166081A
Authority
CN
China
Prior art keywords
alkyl
compound
group
aryl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980078239.1A
Other languages
English (en)
Chinese (zh)
Inventor
J·卡茨
W·鲁斯
H·M·塞德尔
沈东明
S·文卡特拉曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN113166081A publication Critical patent/CN113166081A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980078239.1A 2018-11-13 2019-11-11 用于治疗与nlrp活性相关的病症的化合物和组合物 Pending CN113166081A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862760244P 2018-11-13 2018-11-13
US201862760248P 2018-11-13 2018-11-13
US201862760279P 2018-11-13 2018-11-13
US62/760,248 2018-11-13
US62/760,279 2018-11-13
US62/760,244 2018-11-13
US201962795373P 2019-01-22 2019-01-22
US62/795,373 2019-01-22
US201962796361P 2019-01-24 2019-01-24
US201962796356P 2019-01-24 2019-01-24
US62/796,361 2019-01-24
US62/796,356 2019-01-24
PCT/US2019/060775 WO2020102100A1 (en) 2018-11-13 2019-11-11 Compounds and compositions for treating conditions associated with nlrp activity

Publications (1)

Publication Number Publication Date
CN113166081A true CN113166081A (zh) 2021-07-23

Family

ID=68916531

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980078239.1A Pending CN113166081A (zh) 2018-11-13 2019-11-11 用于治疗与nlrp活性相关的病症的化合物和组合物

Country Status (6)

Country Link
US (1) US12134611B2 (https=)
EP (1) EP3880666B1 (https=)
JP (1) JP2022506898A (https=)
CN (1) CN113166081A (https=)
ES (1) ES2957692T3 (https=)
WO (1) WO2020102100A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117185965A (zh) * 2023-09-18 2023-12-08 安徽金桐精细化学有限公司 一种磺酸基丙烯酸盐复配表面活性剂的制备方法
CN119775202A (zh) * 2024-12-31 2025-04-08 河南旭瑞新材料科技有限公司 一种2-巯基烟酰甘氨酸的合成方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3649112A1 (en) * 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
CA3105521A1 (en) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Sulfonimidamide compounds as inhibitors of interleukin-1 activity
EP3986879B1 (en) * 2019-06-21 2024-10-02 AC Immune SA Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2026064385A1 (en) * 2024-09-18 2026-03-26 Ventus Therapeutics U.S., Inc. Oxadiazolone inhibitors of nlrp3 and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016131098A1 (en) * 2015-02-16 2016-08-25 The University Of Queensland Sulfonylureas and related compounds and use of same
WO2017184604A1 (en) * 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Compounds and compositions for treating conditions associated with nlrp activity
WO2019023145A1 (en) * 2017-07-24 2019-01-31 IFM Tre, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
CN114008030A (zh) * 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
ZA929699B (en) 1991-12-20 1994-06-14 Lilly Co Eli Sulfonimidamides
US5705398A (en) 1994-03-02 1998-01-06 The Scripps Research Institute Methods for identifying inhibitors of LPS-mediated LBP binding
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
CA2329065A1 (en) 1998-05-05 1999-11-11 Francisco Xavier Talamas Pyrazole derivatives as p-38 map kinase inhibitors
KR101120857B1 (ko) 2003-06-26 2012-04-12 노파르티스 아게 5원의 헤테로사이클-기재 ｐ38 키나제 억제제
US20080280910A1 (en) 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
US8884006B2 (en) 2011-09-19 2014-11-11 University Of Puerto Rico Small-molecule inhibitors of Rac1 in metastatic breast cancer
ITMI20131658A1 (it) 2013-10-08 2015-04-09 Getters Spa Combinazione di materiali per dispositivi di rilascio di mercurio e dispositivi contenenti detta combinazione di materiali
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
US11339136B2 (en) 2016-04-18 2022-05-24 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
CA3021349A1 (en) 2016-04-19 2017-10-26 Innate Tumor Immunity, Inc. Nlrp3 modulators
JP6962941B2 (ja) 2016-06-14 2021-11-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Ａｐｊ受容体アゴニストとしての４−ヒドロキシ−３−スルホニルピリジン−２（１ｈ）−オン
EP3571187B1 (en) 2017-01-23 2023-11-22 Genentech, Inc. Chemical compounds as inhibitors of interleukin-1 activity
WO2018225018A1 (en) 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
ES2988798T3 (es) 2017-07-24 2024-11-21 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
EP3668840A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
CA3105521A1 (en) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Sulfonimidamide compounds as inhibitors of interleukin-1 activity
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
BR112021003665A2 (pt) 2018-09-13 2021-05-18 Bayer Aktiengesellschaft derivados de heterocicleno como agentes de controle de pragas
EP3911323A4 (en) 2019-01-18 2022-11-16 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016131098A1 (en) * 2015-02-16 2016-08-25 The University Of Queensland Sulfonylureas and related compounds and use of same
WO2017184604A1 (en) * 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Compounds and compositions for treating conditions associated with nlrp activity
US20190119241A1 (en) * 2016-04-18 2019-04-25 Ifm Therapeutics, Inc Compounds and compositions for treating conditions associated with nlrp activity
WO2019023145A1 (en) * 2017-07-24 2019-01-31 IFM Tre, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
CN114008030A (zh) * 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FLAVIA IZZO等: "Exploration of novel chemical space:synthesis and in vitro evaluation of N-functionalized tertiary sulfonimidamides", CHEMISTRY-A EUROPEAN JOURNAL, vol. 24, no. 37, 19 June 2018 (2018-06-19), pages 9295 - 9304, XP055626913, DOI: 10.1002/chem.201801557 *
GANESH CHANDRA NANDI等: "Direct synthesis of N-acyl sulfonimidamides and N-sulfonimidoyl amidines from sulfonimidoyl azides", ADVANCE SYNTHESIS CATALYSIS, vol. 360, no. 13, 4 July 2018 (2018-07-04), pages 2465 - 2469, XP055506752, DOI: 10.1002/adsc.201800215 *
TOTH J E等: "Sulfonimidamide analogs of oncolytic sulfonylureas", JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 6, 1 January 1997 (1997-01-01), pages 1018 - 1025, XP000926714, DOI: 10.1021/jm960673l *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117185965A (zh) * 2023-09-18 2023-12-08 安徽金桐精细化学有限公司 一种磺酸基丙烯酸盐复配表面活性剂的制备方法
CN119775202A (zh) * 2024-12-31 2025-04-08 河南旭瑞新材料科技有限公司 一种2-巯基烟酰甘氨酸的合成方法

Also Published As

Publication number Publication date
ES2957692T3 (es) 2024-01-24
US20230024859A1 (en) 2023-01-26
EP3880666A1 (en) 2021-09-22
EP3880666B1 (en) 2023-06-28
WO2020102100A1 (en) 2020-05-22
WO2020102100A9 (en) 2022-01-06
JP2022506898A (ja) 2022-01-17
US12134611B2 (en) 2024-11-05

Similar Documents

Publication Publication Date Title
JP7654767B2 (ja) Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
JP7730759B2 (ja) Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物
CN111094242B (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
CN112584899A (zh) Nlrp调节剂
CN113166081A (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113286784A (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113056451A (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113316566A (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113329998A (zh) 用于治疗与nlrp活性相关的病症的磺酰亚胺酰胺化合物和组合物
CN113227055A (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113347970A (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113613721A (zh) Nlrp调节剂
CN113015730A (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
HK40103462A (en) Compounds and compositions for treating conditions associated with nlrp activity
HK40024570B (en) Compounds and compositions for treating conditions associated with nlrp activity
HK40024570A (en) Compounds and compositions for treating conditions associated with nlrp activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210723

WD01 Invention patent application deemed withdrawn after publication